Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.


Journal Article

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Full Text

Duke Authors

Cited Authors

  • Zelenetz, AD; Gordon, LI; Wierda, WG; Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Byrd, JC; Czuczman, MS; Fayad, LE; Fisher, RI; Glenn, MJ; Habermann, TM; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Porcu, P; Press, O; Rabinovitch, R; Reddy, N; Reid, E; Saad, AA; Sokol, L; Swinnen, LJ; Tsien, C; Vose, JM; Wilson, L; Yahalom, J; Zafar, N; Dwyer, M; Sundar, H; National comprehension cancer network,

Published Date

  • March 2015

Published In

Volume / Issue

  • 13 / 3

Start / End Page

  • 326 - 362

PubMed ID

  • 25736010

Pubmed Central ID

  • 25736010

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0045


  • eng

Conference Location

  • United States